Abstract: Disclosed herein are novel variants of clotting factor IX and their use, for example, in methods of treating a subject with a clotting disorder, such as hemophilia A or hemophilia B.

Abstract: Disclosed herein are novel variants of clotting factors VII, VIII, and IX and their use, for example, in methods of treating a subject with a clotting disorder, such as hemophilia A or hemophilia B.

Abstract: Provided herein are compositions and methods for promoting hematopoietic cell cytotoxicity.

Abstract: The systems, devices, and methods utilize devices configured to (i) control the loading of each channel layer and/or (ii) prevent formation of bubbles within the channels. A device may include two or more stacked layers. The two or more stacked layers may include a first layer and a second layer. The first entry region diameter of the first layer and the second entry region diameter of the second layer may be different; and/or the first exit region diameter of the first layer and the second exit region diameter of the second layer may be different; and/or one or more of the first channel dimensions (e.g., length and/or width) of the first layer and the one or more of the second channel dimensions (e.g., length and/or width) of the second layer may be different.

Abstract: Provided herein are nucleic acids, vectors, and cells containing an expression-optimized codon that encodes a Munc13-4 polypeptide or a STXBP2 polypeptide. Also provided are methods of making and using the nucleic acids, vectors, and cells. Also provided herein are methods of treating of Hemophagocytic Lymphohistiocytosis (HLH) in a subject.

Abstract: Provided herein are recombinant AAV (rAAV) serotypes that are useful for targeting innate immune cells. In some embodiments, the rAAV are used to deliver genes encoding one or more receptors that can target the innate immune cells to diseased tissue of interest. In some aspects, the rAAV particle is a rAAV particle having a mutation in a surface-exposed amino acid, such as tyrosine, threonine, or serine, that enhances transduction of dendritic cells.

Abstract: Disclosed herein are novel variants of clotting factors VII, VIII, and IX and their use, for example, in methods of treating a subject with a clotting disorder, such as hemophilia A or hemophilia B.

Abstract: A recombinant von Willebrand Factor (VWF) protein comprising one or more mutations and uses thereof are described. A recombinant protein complex comprising a von Willebrand factor sequence and one artificial Factor VIII sequence is described. A recombinant protein complex comprising a Factor VIII sequence and one artificial von Willebrand sequence is described. A recombinant protein complex is described that includes one artificial von Willebrand factor sequence and one artificial Factor VIII sequence. Also described are nucleic acid sequences and a vector encoding a VWF sequence and a pharmaceutical composition for inducing blood clotting that includes a VWF protein.

Abstract: The present disclosure is generally related to methods for combining chemotherapy and immunotherapy for the treatment of a cancer.

Abstract: The present disclosure is generally related to methods for combining chemotherapy and immunotherapy for the treatment of a cancer. The methods also relate to generating a drug-resistant cytotoxic immune cell line and uses thereof in conjunction with cytotoxic drugs.

Abstract: The present disclosure is generally related to methods for combining chemotherapy and immunotherapy for the treatment of a cancer. The methods also relate to generating a drug-resistant cytotoxic immune cell line and uses thereof in conjunction with cytotoxic drugs.

Abstract: The present disclosure is generally related to methods for combining chemotherapy and immunotherapy for the treatment of a cancer.

Abstract: The present disclosure is generally related to methods for combining chemotherapy and immunotherapy for the treatment of a cancer.